Next-Generation Tumor Localization Marker
Gold-DOT
Gold powder-polymer composite marker for prostate cancer particle therapy — prototype testing confirmed 7,013 HU CT visibility, 8.5% proton and 7.2% carbon-ion dose reduction vs. up to 44.3% for pure-gold markers, with development targets of ≥7,200 HU and ≤7%.
Particle therapy tumor tracking: prototype confirmed 7,013 HU CT visibility (target ≥7,200 HU) and proton dose reduction 8.5% / carbon-ion 7.2% (target ≤7%)CT distortion pixel ratio 23% in prototype — development target ≤15% for more accurate treatment planningGold content ~1/20 of conventional pure-gold markers (prototype-confirmed) — significant cost advantage for particle therapy centersAnti-migration fixation structure ensures stable position reproducibility across all fractions
- Gold powder-polymer (PMMA) composite — gold content ~1/20 of conventional pure-gold markers (prototype-confirmed)
- CT visibility: 7,013 HU measured in prototype → development target ≥7,200 HU
- Proton beam dose reduction: 8.5% measured in prototype → development target ≤7%
- Carbon-ion beam dose reduction: 7.2% measured in prototype → approaching target ≤7%
